185 related articles for article (PubMed ID: 34720156)
1. Fluoxetine in the Management of Major Depressive Disorder in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials.
Reyad AA; Plaha K; Girgis E; Mishriky R
Hosp Pharm; 2021 Oct; 56(5):525-531. PubMed ID: 34720156
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Cariprazine in Acute Management of Psychiatric Disorders: a Meta-Analysis of Randomized Controlled Trials.
Cooper H; Mishriky R; Reyad AA
Psychiatr Danub; 2020; 32(1):36-45. PubMed ID: 32303028
[TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
Weihs KL; Murphy W; Abbas R; Chiles D; England RD; Ramaker S; Wajsbrot DB
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):36-46. PubMed ID: 29189044
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Antoun Reyad A; Girgis E; Mishriky R
Int Clin Psychopharmacol; 2020 May; 35(3):119-128. PubMed ID: 32141908
[TBL] [Abstract][Full Text] [Related]
5. Anxiety as a predictor of treatment outcome in children and adolescents with depression.
Cheung A; Mayes T; Levitt A; Schaffer A; Michalak E; Kiss A; Emslie G
J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):211-6. PubMed ID: 20578934
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.
Maneeton N; Maneeton B; Srisurapanont M; Martin SD
BMC Psychiatry; 2012 Sep; 12():160. PubMed ID: 23017200
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.
Emslie GJ; Rush AJ; Weinberg WA; Kowatch RA; Hughes CW; Carmody T; Rintelmann J
Arch Gen Psychiatry; 1997 Nov; 54(11):1031-7. PubMed ID: 9366660
[TBL] [Abstract][Full Text] [Related]
9. Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial.
McNamara RK; Strawn JR; Tallman MJ; Welge JA; Patino LR; Blom TJ; DelBello MP
J Child Adolesc Psychopharmacol; 2020 Jun; 30(5):293-305. PubMed ID: 32167792
[No Abstract] [Full Text] [Related]
10. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
Beasley CM; Koke SC; Nilsson ME; Gonzales JS
Clin Ther; 2000 Nov; 22(11):1319-30. PubMed ID: 11117656
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials.
Luan S; Wan H; Wang S; Li H; Zhang B
Neuropsychiatr Dis Treat; 2017; 13():609-620. PubMed ID: 28280343
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
Zhou X; Teng T; Zhang Y; Del Giovane C; Furukawa TA; Weisz JR; Li X; Cuijpers P; Coghill D; Xiang Y; Hetrick SE; Leucht S; Qin M; Barth J; Ravindran AV; Yang L; Curry J; Fan L; Silva SG; Cipriani A; Xie P
Lancet Psychiatry; 2020 Jul; 7(7):581-601. PubMed ID: 32563306
[TBL] [Abstract][Full Text] [Related]
13. Can Fluoxetine Combined with Cognitive Behavioral Therapy Reduce the Suicide and Non-Suicidal Self-Injury Incidence and Recurrence Rate in Depressed Adolescents Compared with Fluoxetine Alone? A Meta-Analysis.
Liu W; Li G; Wang C; Yu M; Zhu M; Yang L
Neuropsychiatr Dis Treat; 2022; 18():2543-2557. PubMed ID: 36349346
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine.
Maneeton N; Maneeton B; Eurviriyanukul K; Srisurapanont M
Drug Des Devel Ther; 2013; 7():1053-62. PubMed ID: 24101861
[TBL] [Abstract][Full Text] [Related]
15. Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis.
Maneeton N; Maneeton B; Karawekpanyawong N; Woottiluk P; Putthisri S; Srisurapanon M
Nord J Psychiatry; 2020 Oct; 74(7):461-469. PubMed ID: 32242450
[No Abstract] [Full Text] [Related]
16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.
Arango C; Buitelaar JK; Fegert JM; Olivier V; Pénélaud PF; Marx U; Chimits D; Falissard B;
Lancet Psychiatry; 2022 Feb; 9(2):113-124. PubMed ID: 34919834
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis.
Ma D; Zhang Z; Zhang X; Li L
Curr Med Res Opin; 2014 Jun; 30(6):971-95. PubMed ID: 24188102
[TBL] [Abstract][Full Text] [Related]
19. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine?
Mayes TL; Tao R; Rintelmann JW; Carmody T; Hughes CW; Kennard BD; Stewart SM; Emslie GJ
CNS Spectr; 2007 Feb; 12(2):147-54. PubMed ID: 17277715
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.
Radecki DT; Robieson WZ; Gopalkrishnan M; Greenberg E; Aziz M
J Child Adolesc Psychopharmacol; 2024 May; ():. PubMed ID: 38700708
[No Abstract] [Full Text] [Related]
[Next] [New Search]
